Mark W. Albers is a neurologist specializing in memory and olfactory disorders. At Mass General he sees patients in the Memory Disorders Clinic and attends on the inpatient neurologic wards. His clinical research is focused on developing sensitive probes of olfactory function as a biomarker for early neurodegenerative disease, including Alzheimer’s and TBI, and COVID. His laboratory research focuses on elucidating the mechanisms of neurodegenera-tion, identifying novel drug targets that mediate neurodegeneration, and developing therapies to prevent neurodegeneration. He is the overall PI of the NADALS trial, the first basket trial in neurodegenerative disease. The drug repurposing, baricitinib, will be tested in patient popula-tions with either Alzheimer’s disease or ALS in this trial. He served as a member of the Trans-lational Neuroscience committee of the American Academy of Neurology, is a faculty member of the Harvard Program in Therapeutic Science, the Laboratory of Systems Pharmacology, the Harvard-MIT Center for Regulatory Science, and the McCance Center for Brain Health. He is the Associate Director of the Massachusetts Center for Alzheimer’s Therapeutic Science.